Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study.
Alice MarkussenJulia Sidenius JohansenFinn O LarsenSusann TheileJane P HasselbyGro L WillemoeTorben LorentzenKasper MadsenEstrid V S HøgdallTim Svenstrup PoulsenEva E WilkenPoul GeertsenClaus Preibisch BehrensInge Marie SvaneDorte Lisbet NielsenInna Markovna ChenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Combining SBRT, nivolumab, and ipilimumab is well tolerated, feasible, and shows response in a subgroup of patients with mBTC.